These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30641705)

  • 21. Acute effects of fructose consumption on uric acid and plasma lipids in patients with impaired renal function.
    Zawiasa A; Nowicki M
    Metabolism; 2013 Oct; 62(10):1462-9. PubMed ID: 23866980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum fructosamine as a marker of 5-year risk of developing diabetes mellitus in patients exhibiting stress hyperglycaemia.
    Wahid ST; Sultan J; Handley G; Saeed BO; Weaver JU; Robinson AC
    Diabet Med; 2002 Jul; 19(7):543-8. PubMed ID: 12099956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.
    Shehata M; Hamza M
    Cardiovasc Ther; 2015 Apr; 33(2):35-41. PubMed ID: 25677920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and severity of anaemia in patients with type 2 diabetic nephropathy and different degrees of chronic renal insufficiency.
    Li Vecchi M; Fuiano G; Francesco M; Mancuso D; Faga T; Sponton A; Provenzano R; Andreucci M; Tozzo C
    Nephron Clin Pract; 2007; 105(2):c62-7. PubMed ID: 17135770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum bisphenol A and progression of type 2 diabetic nephropathy: a 6-year prospective study.
    Hu J; Yang S; Wang Y; Goswami R; Peng C; Gao R; Zhou H; Zhang Y; Cheng Q; Zhen Q; Li Q
    Acta Diabetol; 2015 Dec; 52(6):1135-41. PubMed ID: 26321107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
    Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
    Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Excess renal insufficiency among type 2 diabetic patients with dip-stick positive proteinuria in a tertiary hospital.
    Balogun WO; Abbiyesuku FM
    Afr J Med Med Sci; 2011 Dec; 40(4):399-403. PubMed ID: 22783692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum N-terminal Pro-brain Natriuretic Peptide Level is Associated with the Development of Chronic Kidney Diseases in Patients with Type 2 Diabetes.
    Sawada R; Hashimoto Y; Senmaru T; Tanaka M; Ushigome E; Yamazaki M; Fukui M
    Endocr Metab Immune Disord Drug Targets; 2018; 18(6):590-595. PubMed ID: 29697035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial.
    Tan SMQ; Chiew Y; Ahmad B; Kadir KA
    Nutrients; 2018 Sep; 10(9):. PubMed ID: 30227659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology and risk factors for chronic kidney disease in patients with ischaemic stroke.
    Bao YS; Song LT; Zhong D; Song AX; Jia XB; Liu RC; Xie RJ; Na SP
    Eur J Clin Invest; 2013 Aug; 43(8):829-35. PubMed ID: 23869408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus.
    Penno G; Russo E; Garofolo M; Daniele G; Lucchesi D; Giusti L; Sancho Bornez V; Bianchi C; Dardano A; Miccoli R; Del Prato S
    Diabetologia; 2017 Jun; 60(6):1102-1113. PubMed ID: 28357502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study.
    Ray S; Beatrice AM; Ghosh A; Pramanik S; Bhattacharjee R; Ghosh S; Raychaudhury A; Mukhopadhyay S; Chowdhury S
    Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S931-S937. PubMed ID: 28728874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetic kidney disease and obstructive sleep apnea: a new frontier?
    Al Mawed S; Unruh M
    Curr Opin Pulm Med; 2016 Jan; 22(1):80-8. PubMed ID: 26574721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progression of nephropathy in type 2 diabetes: the glycation gap is a significant predictor after adjustment for glycohemoglobin (Hb A1c).
    Rodríguez-Segade S; Rodríguez J; Cabezas-Agricola JM; Casanueva FF; Camiña F
    Clin Chem; 2011 Feb; 57(2):264-71. PubMed ID: 21147957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum omentin-1 levels in diabetic and nondiabetic patients with chronic kidney disease.
    Tekce H; Tekce BK; Aktas G; Alcelik A; Sengul E
    Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):451-6. PubMed ID: 24918534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorophores advanced glycation end products (AGEs)-to-NADH ratio is predictor for diabetic chronic kidney and cardiovascular disease.
    Ciobanu DM; Olar LE; Stefan R; Veresiu IA; Bala CG; Mircea PA; Roman G
    J Diabetes Complications; 2015; 29(7):893-7. PubMed ID: 26169772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diabetic Kidney Disease 3rd stage - laboratory markers of mineral bone disorder].
    Klimentová A; Ságová I; Prídavková D; Kantárová D; Makovický P; Sadloňová J; Mokáň M
    Vnitr Lek; 2016; 62(6):442-8. PubMed ID: 27485841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemorheological Approach for Early Detection of Chronic Kidney Disease and Diabetic Nephropathy in Type 2 Diabetes.
    Lee S; Lee MY; Nam JS; Kang S; Park JS; Shin S; Ahn CW; Kim KR
    Diabetes Technol Ther; 2015 Nov; 17(11):808-15. PubMed ID: 26214546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carbamylation is a competitor of glycation for protein modification in vivo.
    Nicolas C; Jaisson S; Gorisse L; Tessier FJ; Niquet-Léridon C; Jacolot P; Pietrement C; Gillery P
    Diabetes Metab; 2018 Mar; 44(2):160-167. PubMed ID: 28690125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of Endothelial Cell Injury Marker Cd146 Correlates with Disease Severity and Predicts the Renal Outcomes in Patients with Diabetic Nephropathy.
    Fan Y; Fei Y; Zheng L; Wang J; Xiao W; Wen J; Xu Y; Wang Y; He L; Guan J; Wei J; He JC; Wang N
    Cell Physiol Biochem; 2018; 48(1):63-74. PubMed ID: 30001528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.